{
    "@graph": [
        {
            "@id": "gnd:1217212264",
            "sameAs": "Srivastava, Ved"
        },
        {
            "@id": "https://www.tib.eu/de/suchen/id/TIBKAT%3A1676790179",
            "@type": "bibo:Book",
            "P1053": "1 Online-Ressource (xxvii, 543 Seiten)",
            "description": [
                "Campusweiter Zugriff (Universit\u00e4t Hannover).- Vervielf\u00e4ltigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots.",
                "Illustrationen, Diagramme"
            ],
            "identifier": [
                "(isbn13)9781788016445",
                "(ppn)1676790179",
                "(firstid)KXP:1676790179",
                "(doi)10.1039/9781788016445"
            ],
            "publisher": "Royal Society of Chemistry",
            "subject": [
                "(classificationName=loc)RS431.P38",
                "(classificationName=ddc)615.19",
                "Peptide drugs",
                "(classificationName=linseach:mapping)rest",
                "(classificationName=ddc)615.1/9",
                "Peptides"
            ],
            "title": "Peptide therapeutics : strategy and tactics for chemistry, manufacturing, and controls",
            "abstract": [
                "Cover; Preface; Editor Biography; Contents; Chapter 1 Regulatory Considerations for Peptide Therapeutics; 1.1 Introduction; 1.2 Peptide Quality Assessment at the FDA; 1.3 Overview of the Current Drug Approval Process Employed for Peptide Applications; 1.3.1 The New Drug Application Assessment Process; 1.3.2 Abbreviated New Drug Application Assessment Process; 1.3.3 Post-approval Activities and Life-cycle Management; Disclaimer; Acknowledgements; References; Chapter 2 Regulatory Perspective on Synthetic Peptides in Europe; 2.1 Introduction; 2.2 European Regulatory Network",
                "3.5.8 Cytometry-based Immunoassays3.5.9 Acid Dissociation-based Assay for Drug Interference; 3.5.10 Considerations for Binding Antibody Immunoassays; 3.6 Neutralizing Anti-drug Antibody Testing; 3.6.1 Cell-based Neutralizing Antibody Assay; 3.6.2 Cell Line Selection; 3.6.3 Assay Endpoints for Cell-based Assays; 3.6.4 Cell-based Assay Formats; 3.6.5 Considerations for Ligand-binding Antibody Bioassays; 3.7 Specific Assays for Peptide-based Vaccines; 3.7.1 Enzyme-linked Immunospot (ELISpot) Assay; 3.7.2 Surface and Intracellular Staining; 3.8 Conclusion; References",
                "3.3 Assay Development and Validation3.3.1 Ex Vivo Bioassays; 3.3.2 In Vitro Bioassays; 3.3.3 Assay Readouts; 3.3.4 Assay Design; 3.3.5 Cell Line Selection; 3.3.6 Factors Influencing the Assays; 3.3.7 Standards and Controls; 3.3.8 Design of Experiments and Data Analysis; 3.3.9 Assay Validation; 3.4 Specific Assays of Peptide-based Vaccines; 3.4.1 HLA Binding Assays; 3.5 Immunogenicity Evaluation; 3.5.1 Antibody Testing Strategy; 3.5.2 Risk-based Antibody Testing; 3.5.3 Binding Antibody Testing; 3.5.4 Sandwich Immunoassay; 3.5.5 Mass-related Immunoassay; 3.5.6 SPR; 3.5.7 Mass Spectrometry",
                "2.12 Synthetic Peptide Development Programmes Using a Biological Medicinal Product as a European Reference Medicinal Product2.13 Requirements for Clinical Trial Applications; 2.14 Scientific Advice and European Initiatives for Early Access Approaches; 2.15 Conclusion; Disclaimer; References; Chapter 3 Biological and Immunogenicity Evaluation Strategy for Therapeutic Peptides: Chemistry, Manufacturing and Controls Perspective; 3.1 Introduction; 3.2 Biological Evaluation; 3.2.1 Strategy for Assay Development; 3.2.2 Considerations for Potency Assay Design and Validation",
                "Peptide Therapeutics is an essential reference work for students and researchers, in both academia and industry, with an interest in learning about Chemistry Manufacture and Control (CMC), and facilitating the development and manufacture of peptide-based drugs",
                "2.3 Guidelines on the Quality of Human Medicines2.4 Overall Control Strategy; 2.5 Documentation in Dossier of Marketing Authorization; 2.6 European Pharmacopoeia (Ph. Eur.); 2.7 Technical Guide for the Elaboration of Monographson Synthetic Peptides and Recombinant DNA Proteins; 2.8 Information to be Provided in Module 3 for Synthetic Peptides (New Active Substances); 2.9 Considerations for Peptides Conjugates; 2.10 Medicinal Product Considerations; 2.11 Synthetic Peptide Vaccines"
            ],
            "contributor": [
                "Technische Informationsbibliothek (TIB)",
                {
                    "@id": "gnd:1217212264"
                }
            ],
            "isPartOf": "(collectioncode)ZDB-1-RSEK",
            "issued": "2019",
            "language": "http://id.loc.gov/vocabulary/iso639-1/en",
            "license": "commercial licence",
            "medium": "rda:termList/RDACarrierType/1018",
            "volume": "72",
            "isLike": "doi:10.1039/9781788016445",
            "P30128": "Drug discovery series",
            "P60163": "Cambridge"
        }
    ],
    "@id": "urn:x-arq:DefaultGraphNode",
    "@context": {
        "sameAs": "http://www.w3.org/2002/07/owl#sameAs",
        "abstract": "http://purl.org/dc/terms/abstract",
        "license": "http://purl.org/dc/terms/license",
        "subject": "http://purl.org/dc/elements/1.1/subject",
        "title": "http://purl.org/dc/elements/1.1/title",
        "identifier": "http://purl.org/dc/elements/1.1/identifier",
        "description": "http://purl.org/dc/elements/1.1/description",
        "contributor": "http://purl.org/dc/terms/contributor",
        "language": {
            "@id": "http://purl.org/dc/terms/language",
            "@type": "@id"
        },
        "P1053": "http://iflastandards.info/ns/isbd/elements/P1053",
        "isLike": {
            "@id": "http://umbel.org/umbel#isLike",
            "@type": "@id"
        },
        "medium": {
            "@id": "http://purl.org/dc/terms/medium",
            "@type": "@id"
        },
        "volume": "http://purl.org/ontology/bibo/volume",
        "issued": "http://purl.org/dc/terms/issued",
        "publisher": "http://purl.org/dc/elements/1.1/publisher",
        "P60163": "http://www.rdaregistry.info/Elements/u/#P60163",
        "isPartOf": "http://purl.org/dc/terms/isPartOf",
        "P30128": "http://www.rdaregistry.info/Elements/m/#P30128",
        "umbel": "http://umbel.org/umbel#",
        "rdau": "http://www.rdaregistry.info/Elements/u/#",
        "owl": "http://www.w3.org/2002/07/owl#",
        "dcterms": "http://purl.org/dc/terms/",
        "bibo": "http://purl.org/ontology/bibo/",
        "rdam": "http://www.rdaregistry.info/Elements/m/#",
        "gnd": "http://d-nb.info/gnd/",
        "isbd": "http://iflastandards.info/ns/isbd/elements/",
        "rda": "http://rdvocab.info/",
        "doi": "https://doi.org/"
    }
}